Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,022 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Initial Surgery Clear all

Conditions: Acute Kidney Injury
Interventions: Pantoprazole, Famotidine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Cancer
Interventions: Sunitinib Malate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Post-bariatric Hypoglycemia
Interventions: Avexitide; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 4
States / cities: Boston, Massachusetts • Morehead City, North Carolina • Mesquite, Texas + 1 more

Conditions: Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
Interventions: pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection; Biological · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 39 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Gallbladder Adenocarcinoma
Interventions: HIPEC; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Breast Cancer, LCIS, DCIS
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 72 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hyperglycemia
Interventions: Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion; Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Chicago Heights, Illinois • Albuquerque, New Mexico

Conditions: Neuroblastoma
Interventions: Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor, Cyclophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, PBSC, Radiation Therapy, 13-cis-retinoic acid; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Rectal Cancer
Interventions: Cetuximab, 5-Fluorouracil, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee

Conditions: Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Interventions: Mirdametinib; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 24 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neuroblastoma
Interventions: Vorinostat, 131- I Metaiodobenzylguanidine, Peripheral Blood Stem Cell Infusion, Filgrastim; Drug · Radiation · Procedure
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 2 Years to 30 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Spine Surgery, Wounds Vac
Interventions: Wound Vac, Standard Dressing; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium, Flutamide, Ketoconazole, Nilutamide, Therapeutic Hydrocortisone, Vinblastine, Conventional Surgery; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastric Bypass Surgery Pain Management
Interventions: Real TMS 45 min, Sham TMS 45 min, Real TMS 4 Hours, Sham TMS 4 Hours; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Ischemic Heart Disease
Interventions: Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
Interventions: Wearable Bladder Modulation System; Device
Lead sponsor: Avation Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Englewood, Colorado + 6 more

Conditions: Pain, Postoperative
Interventions: CYP2D6-guided opioid therapy; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Gainesville, Florida • Summerfield, Florida

Conditions: Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions: Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab; Radiation · Drug
Lead sponsor: Mark Bernard; Other
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Unspecified Atrophy of Edentulous Alveolar Ridge
Interventions: Immediate implant placement with simultaneous bone grafting; Procedure
Lead sponsor: Lithuanian University of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Neuromuscular Block, Residual
Interventions: Quantitative monitoring, Qualitative monitoring; Device · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease, Sickle Cell Anemia, SCD
Interventions: Fludarabine, Hematopoietic Stem Cell Transplant (HSCT); Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Development, Child, Adherence, Patient, Congenital Heart Disease
Interventions: Babysparks Application, pre and post-test Redcap Survey; Device · Other
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 18 Months
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Tumor: Breast Ratio Study

Comparative Trial Between 3 Types of Insulin Infusion Protocols

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Prophylactic Application of an Incisional Wound Vac to Prevent Wound Complications in Obese Spine Surgery Patients

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Transcranial Magnetic Stimulation Effects on Pain Perception

Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

FREEOAB Study for Overactive Bladder

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Immediate Implant Placement in the Esthetic Zone

Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

BabySparks Developmental Application Pilot Study